(Q44000891)

28 November 2017

Antiflagellin antibodies suggest infective participation in irritable bowel syndrome pathogenesis (English)

1 reference

28 November 2017

irritable bowel syndrome

1 reference

Cesare Cremon

1

1 reference

28 November 2017

Francesca Pallotti

2

1 reference

28 November 2017

Maddalena Bacchilega

3

1 reference

28 November 2017

Vincenzo Stanghellini

4

1 reference

28 November 2017

Roberto Corinaldesi

5

1 reference

28 November 2017

Giovanni Barbara

6

1 reference

28 November 2017

1 December 2008

1 reference

Expert Review of Gastroenterology & Hepatology

28 November 2017

1 reference

28 November 2017

2

1 reference

28 November 2017

6

1 reference

28 November 2017

735-740

1 reference

Functional bowel disorders

28 November 2017

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.6.735

New pathophysiological mechanisms in irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.6.735

Role for protease activity in visceral pain in irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.6.735

Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.6.735

Interactions between commensal bacteria and gut sensorimotor function in health and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.6.735

Irritable bowel syndrome and inflammatory bowel disease: interrelated diseases?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.6.735

Relevance of serologic studies in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.6.735

Flag in the crossroads: flagellin modulates innate and adaptive immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.6.735

Symptoms of irritable bowel syndrome in ulcerative colitis in remission

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.6.735

Antibodies to CBir1 flagellin define a unique response that is associated independently with complicated Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.6.735

A role for inflammation in irritable bowel syndrome?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.6.735

Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.6.735

Relative importance of enterochromaffin cell hyperplasia, anxiety, and depression in postinfectious IBS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.6.735

Functional gastrointestinal disorders and mast cells: implications for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.6.735

Diarrhoea-predominant IBS patients show mast cell activation and hyperplasia in the jejunum.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.6.735

Increased capsaicin receptor TRPV1-expressing sensory fibres in irritable bowel syndrome and their correlation with abdominal pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.6.735

Mast cells and cellularity of the colonic mucosa correlated with fatigue and depression in irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.6.735

Mucosal mast cell counts correlate with visceral hypersensitivity in patients with diarrhea predominant irritable bowel syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.6.735

Hypothalamic-pituitary-gut axis dysregulation in irritable bowel syndrome: plasma cytokines as a potential biomarker?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.6.735

Immune activation in patients with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.6.735

Unravelling the pathogenesis of inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.6.735

Alterations in mucosal immunity identified in the colon of patients with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.6.735

Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.6.735

Probiotics and irritable bowel syndrome: rationale and clinical evidence for their use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.6.735

The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.6.735

TLRs in the Gut. III. Immune responses to flagellin in Crohn's disease: good, bad, or irrelevant?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.6.735

Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.6.735

21 January 2018

Identifiers

DOI

10.1586/17474124.2.6.735

1 reference

28 November 2017

1 reference